Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions

[1]  D. Goldsmith,et al.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression , 2016, Molecular Psychiatry.

[2]  Livia Puljak,et al.  Extracting data from figures with software was faster, with higher interrater reliability than manual extraction. , 2016, Journal of clinical epidemiology.

[3]  Klaus P. Ebmeier,et al.  Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder , 2015, Brain, Behavior, and Immunity.

[4]  L. Gossec,et al.  Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study. , 2015, Clinical and experimental rheumatology.

[5]  K. Stein,et al.  Tumour necrosis factor-α inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety. , 2015, Journal of psychosomatic research.

[6]  M. Worm,et al.  Dupilumab Improves Patient-Reported Outcomes (PROs) in a Phase 2 Study in Adults with Moderate-to-Severe Atopic Dermatitis , 2015 .

[7]  O. Mors,et al.  Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. , 2014, JAMA psychiatry.

[8]  Georgia E. Hodes,et al.  Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress , 2014, Proceedings of the National Academy of Sciences.

[9]  Peter B. Jones,et al.  Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. , 2014, JAMA psychiatry.

[10]  R. Abouqal,et al.  Responsiveness of the EuroQol EQ-5D and Hospital Anxiety and Depression Scale (HADS) in rheumatoid arthritis patients receiving tocilizumab , 2014, Clinical Rheumatology.

[11]  A. von Deimling,et al.  Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR , 2014, Oncotarget.

[12]  S. Kotak,et al.  Open-Label Observation of Addition of Etanercept Versus a Conventional Disease-Modifying Antirheumatic Drug in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy in the Latin American Region , 2014, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[13]  R. Treister,et al.  Anti tumor Necrosis Factor ‐ Alpha Adalimumab for Complex Regional Pain Syndrome Type 1 (CRPS‐I): A Case Series , 2013, Pain practice : the official journal of World Institute of Pain.

[14]  J. Koo,et al.  A prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions. , 2013, Journal of the American Academy of Dermatology.

[15]  C. Pariante,et al.  Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. , 2013, Journal of affective disorders.

[16]  E. Celius,et al.  Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting , 2013, PloS one.

[17]  B. Nordestgaard,et al.  Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals. , 2013, JAMA psychiatry.

[18]  S. Bae,et al.  Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis , 2013, BMC Musculoskeletal Disorders.

[19]  S. Tyring,et al.  Patient‐reported outcomes in moderate‐to‐severe plaque psoriasis with scalp involvement: results from a randomized, double‐blind, placebo‐controlled study of etanercept , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[20]  A. Zbrozek,et al.  Self‐reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  X. Forns,et al.  Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. , 2012, The Journal of clinical psychiatry.

[22]  A. Akdoğan,et al.  Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level , 2012, Rheumatology International.

[23]  Antti Malmivaara,et al.  Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis , 2012, PloS one.

[24]  K. Reich,et al.  Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta‐analysis of randomized controlled trials , 2012, The British journal of dermatology.

[25]  D. Moher,et al.  CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2011, BMJ : British Medical Journal.

[26]  A. Hinz,et al.  Normative values for the hospital anxiety and depression scale (HADS) in the general German population. , 2011, Journal of psychosomatic research.

[27]  D. Christmas,et al.  A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase , 2011, Neuropsychiatric disease and treatment.

[28]  Daniel J Buysse,et al.  The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. , 2010, Journal of clinical epidemiology.

[29]  S. Feldman,et al.  Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. , 2010, Journal of the American Academy of Dermatology.

[30]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[31]  M. Pittler.  Systematic Reviews in Health Care: Meta‐analysis in Context , 2010 .

[32]  N. Bansback,et al.  PSS17 IMPACT OF ADALIMUMAB ON QUALITY OF LIFE AND DEPRESSION IN PSORIASIS PATIENTS: RESULTS FROM PRIDE , 2010 .

[33]  A. Menter,et al.  The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. , 2010, Journal of the American Academy of Dermatology.

[34]  Thomas Singer,et al.  The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.

[35]  Matthias Egger,et al.  CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.

[36]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Major Depression , 2010, Biological Psychiatry.

[37]  Philip D. Harvey,et al.  Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? , 2009, Journal of affective disorders.

[38]  H. Critchley,et al.  Inflammation Causes Mood Changes Through Alterations in Subgenual Cingulate Activity and Mesolimbic Connectivity , 2009, Biological Psychiatry.

[39]  T. Peters,et al.  Therapist-delivered internet psychotherapy for depression in primary care: a randomised controlled trial , 2009, The Lancet.

[40]  J. Ortonne,et al.  Improvements in patient‐reported outcomes in moderate‐to‐severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[41]  R. Yoshimura,et al.  Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[42]  R. Moots,et al.  Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial , 2009, Annals of the rheumatic diseases.

[43]  J. Suls,et al.  Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis , 2009, Psychosomatic medicine.

[44]  D. Rubin,et al.  Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial , 2008, The American Journal of Gastroenterology.

[45]  N. Rose,et al.  Sex differences in autoimmune disease from a pathological perspective. , 2008, The American journal of pathology.

[46]  M G Marmot,et al.  Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study , 2008, Psychological Medicine.

[47]  A. Kimball,et al.  Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[48]  Blair T. Johnson,et al.  Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.

[49]  P. Geborek,et al.  Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. , 2007, Rheumatology.

[50]  Alex J Sutton,et al.  Performance of the trim and fill method in the presence of publication bias and between‐study heterogeneity , 2007, Statistics in medicine.

[51]  C. Nemeroff,et al.  Prevalence and management of treatment-resistant depression. , 2007, The Journal of clinical psychiatry.

[52]  J. Newcomer,et al.  Identifying metabolic risks with antipsychotics and monitoring and management strategies. , 2007, The Journal of clinical psychiatry.

[53]  M. Samsom,et al.  Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue? , 2007, World journal of gastroenterology.

[54]  P. Scully,et al.  Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. , 2007, Journal of psychiatric research.

[55]  Erkki Isometsä,et al.  Temperament, character and symptoms of anxiety and depression in the general population , 2006, European Psychiatry.

[56]  H. Möller,et al.  The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine , 2006, Molecular Psychiatry.

[57]  A. Gottlieb,et al.  Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial , 2006, The Lancet.

[58]  A. Miller,et al.  Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function , 2005, Molecular Psychiatry.

[59]  M. Posternak,et al.  A Review of Studies of the Hamilton Depression Rating Scale in Healthy Controls: Implications for the Definition of Remission in Treatment Studies of Depression , 2004, The Journal of nervous and mental disease.

[60]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[61]  C. Nemeroff,et al.  Neurobehavioral Effects of Interferon-α in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions , 2002, Neuropsychopharmacology.

[62]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[63]  T. Pollmächer,et al.  Cytokine-associated emotional and cognitive disturbances in humans. , 2001, Archives of general psychiatry.

[64]  Carmine M Pariante,et al.  Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment , 2001, Biological Psychiatry.

[65]  S. Chinn.  A simple method for converting an odds ratio to effect size for use in meta-analysis. , 2000, Statistics in medicine.

[66]  S Duval,et al.  Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis , 2000, Biometrics.

[67]  E. Bosmans,et al.  Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. , 1997, Cytokine.

[68]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[69]  Michael Maes,et al.  Evidence for an immune response in major depression: A review and hypothesis , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[70]  G. Spears,et al.  Some norms and reliability data for the State--Trait Anxiety Inventory and the Zung Self-Rating Depression scale. , 1983, The British journal of clinical psychology.

[71]  D. F. Drake,et al.  A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. , 2013, JAMA psychiatry.

[72]  R. Dantzer,et al.  Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. , 2009, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[73]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[74]  Andrew H. Miller,et al.  Cytokines sing the blues: inflammation and the pathogenesis of depression. , 2006, Trends in immunology.

[75]  D. Musselman,et al.  Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. , 2002, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[76]  Douglas G. Altman,et al.  Systematic Reviews in Health Care , 2001 .

[77]  Mika Kivimäki,et al.  Cumulative meta-analysis of interleukins 6 and 1 beta , tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder , 2022 .